Imbruvica - (70MG/1ML ; Suspension)

Generic Name	Ibrutinib	**Innovator**	Pharmacyclics
Dosage	70MG/1ML ; Suspension	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with: • Mantle cell lymphoma (MCL) who have received at least one prior therapy. • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. • Waldenström's macroglobulinemia (WM). • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. • Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.